Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial
暂无分享，去创建一个
R. Gansevoort | A. Chapman | M. Irazabal | V. Torres | P. Harris | C. M. Heyer | O. Devuyst | R. Perrone | J. Ouyang | F. Czerwiec | Sarah R. Senum | J. Blais | Y. Le Meur | E. Cornec-Le Gall | Emilie Cornec-Le Gall | Jaime D. Blais | Maria V. Irazabal | Olivier Devuyst | Ron T. Gansevoort | Ron D. Perrone | Arlene B. Chapman | Frank S. Czerwiec | John Ouyang | Christina M. Heyer | Sarah R. Senum | Yannick Le Meur | Vicente E. Torres | Peter C. Harris